Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2022-04-15 00:00:00 ET · period of report 2022-04-14 · accession 0001567619-22-008613 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-15 | 2022-04-14 | PYXS | Sullivan Lara | CEO, Dir | A - Grant | $0.00 | +315.3K | 1.36M | +30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-14 | A | A | 315,273 | $0.00 | 1,356,636 | D | — | — | (F3) The Compensation Committee also approved a grant to the Reporting Person of $200,000 cash compensation that is payable in full on April 13, 2023, subject to the Reporting Person's continued employment through the payment date. (F2) The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 95,684 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates. (F1) Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date. |